Legend Biotech (LEGN) Cost of Revenue (2022 - 2026)
Legend Biotech's (LEGN) quarterly Cost of Revenue came in at $175.4 million in Q1 2026, up 152.37% YoY from $69.5 million in Q1 2025, and up 54.86% on a QoQ basis from $113.3 million in Q3 2025.
Legend Biotech (LEGN) Cost of Revenue (2022 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 5 years of Cost of Revenue data on file, last reported at $175.4 million in Q1 2026.
- Quarterly Cost of Revenue rose 152.37% year-over-year to $175.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $453.0 million (up 91.34% YoY) and the FY2024 annual result came in at $216.4 million, up 50.03% from the prior year.
- Cost of Revenue grew to $175.4 million in Q1 2026, from $113.3 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $175.4 million in Q1 2026 to a low of $23.0 million in Q4 2022.
- A 5-year average of $61.6 million and a median of $47.2 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2024 — Cost of Revenue grew 20.77% — and 2026, when it jumped 152.37%.
- Tracing LEGN's Cost of Revenue over 5 years: stood at $23.0 million in 2022, then surged by 41.31% to $32.4 million in 2023, then soared by 113.86% to $69.4 million in 2024, then soared by 63.21% to $113.3 million in 2025, then jumped by 54.86% to $175.4 million in 2026.
- The last three Cost of Revenue figures came in at $175.4 million (Q1 2026), $113.3 million (Q3 2025), and $94.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 136.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 136.00 Mn |
| Jun 30, 2026 | 136.00 Mn |
| Mar 31, 2026 | 175.40 Mn |
| Mar 31, 2026 | 175.40 Mn |
| Sep 30, 2025 | 113.26 Mn |
| Sep 30, 2025 | 113.26 Mn |
| Jun 30, 2025 | 94.87 Mn |
| Jun 30, 2025 | 94.87 Mn |
| Mar 31, 2025 | 69.50 Mn |
| Mar 31, 2025 | 69.50 Mn |
| Dec 31, 2024 | 69.40 Mn |
| Dec 31, 2024 | 69.40 Mn |
| Sep 30, 2024 | 52.51 Mn |
| Sep 30, 2024 | 52.51 Mn |
| Jun 30, 2024 | 45.36 Mn |
| Jun 30, 2024 | 45.36 Mn |
| Mar 31, 2024 | 49.10 Mn |
| Mar 31, 2024 | 49.10 Mn |
| Dec 31, 2023 | 32.45 Mn |
| Dec 31, 2023 | 32.45 Mn |